



ASX RELEASE
17 December 2013

**Appendices 3Y Lodged on 16th December 2013 by Tissue Therapies Limited
(Issuer) (ASX Code: TIS)**

Tissue Therapies Limited (**Tissue**) lodged Appendices 3Y on 16th December 2013 in order to correct the disclosure of Director interests in Tissue Therapies Limited in respect of Melvyn Bridges and Steven Mercer.

By way of explanation, on reviewing the previous Appendices 3Y lodged in respect of these Directors, it was established that the information previously disclosed in respect of Dr Bridges contained minor inaccuracies and that Appendix 3Y's had not been lodged in respect of 125,000 ordinary shares issued to Dr Mercer on exercise of options.

The Company has reviewed and reinforced its procedures to ensure that Directors' interests are disclosed in accordance with Listing Rule 3.19A in future.

Signed for and on behalf of Tissue:

Drummond McKenzie
Company Secretary
Tissue Therapies Limited

What is VitroGro[®] ECM

- VitroGro[®] ECM is a topically applied, biomimetic scaffold, comprising a synthetic extracellular matrix (ECM) protein.
- How it works: VitroGro[®] ECM replaces the degraded matrix of a hard to heal wound. VitroGro[®] ECM binds to a prepared wound bed and provides a physical structure (a scaffold) for cell attachment, which is a primary requirement for subsequent cell functions critical for healing, such as cell proliferation and migration ^[1].
- An optimal scaffold: One of the characteristics of hard to heal wounds is prolonged inflammation, which damages the native ECM that would normally guide the wound healing process ^[1,2,3,4]. Replacement of this damaged ECM is a beneficial strategy for treating hard to heal wounds ^[1]. VitroGro[®] ECM is ideal as an ECM replacement since its structural and functional elements mimic those present in the ECM at the early stages of normal wound healing.
- Expert health economics modelling indicates that VitroGro[®] ECM offers the opportunity for substantially more cost effective treatment of wounds compared to the current standard of care.

[1] Widgerow AD . Deconstructing the stalled wound. Wounds 2012

[2] Schultz GS. Extracellular Matrix: review of its roles in acute and chronic wounds. World Wide Wounds. 2005

[3] Moor AN. et al. Proteolytic activity in wound fluids and tissues derived from chronic venous leg ulcers. Wound Rep Reg. 2009

[4] International consensus, Acellular matrices for treatment of wounds. Wounds Int. 2010

About Tissue Therapies Limited

Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns. Tissue Therapies Limited is commercialising VitroGro[®] ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The company is also developing treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate. Tissue Therapies Limited's shares are traded on the Australian, Berlin and Frankfurt stock exchanges.

More information: www.tissuetherapies.com